LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

TG Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

31.57 1.58

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

31.14

Max

32.55

Galvenie mērījumi

By Trading Economics

Ienākumi

23M

28M

Pārdošana

20M

141M

P/E

Sektora vidējais

77.184

35.733

Peļņas marža

19.97

Darbinieki

370

EBITDA

25M

38M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+1.43% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

94M

4.7B

Iepriekšējā atvēršanas cena

29.99

Iepriekšējā slēgšanas cena

31.57

Ziņu noskaņojums

By Acuity

29%

71%

97 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

TG Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 8. sept. 23:59 UTC

Iegādes, apvienošanās, pārņemšana

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025. g. 8. sept. 22:02 UTC

Galvenie tirgus virzītāji

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025. g. 8. sept. 17:01 UTC

Galvenie tirgus virzītāji

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025. g. 8. sept. 17:01 UTC

Galvenie tirgus virzītāji

Tron Shares Rise After New Investment From Bravemorning

2025. g. 8. sept. 16:14 UTC

Galvenie tirgus virzītāji

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025. g. 8. sept. 16:13 UTC

Galvenie tirgus virzītāji

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025. g. 8. sept. 22:56 UTC

Tirgus saruna

Worst May Be Over for New Zealand Retailers -- Market Talk

2025. g. 8. sept. 22:23 UTC

Tirgus saruna

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025. g. 8. sept. 21:51 UTC

Tirgus saruna

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025. g. 8. sept. 21:47 UTC

Galvenie tirgus virzītāji

Microsoft Signs $17.4B AI Deal With Nebius

2025. g. 8. sept. 21:33 UTC

Iegādes, apvienošanās, pārņemšana

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025. g. 8. sept. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025. g. 8. sept. 21:19 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025. g. 8. sept. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025. g. 8. sept. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. sept. 19:33 UTC

Tirgus saruna

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025. g. 8. sept. 19:22 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025. g. 8. sept. 19:02 UTC

Tirgus saruna

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025. g. 8. sept. 18:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. sept. 18:24 UTC

Tirgus saruna

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025. g. 8. sept. 17:29 UTC

Tirgus saruna

Mexican Inflation Seen Little Changed in August -- Market Talk

2025. g. 8. sept. 16:59 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025. g. 8. sept. 16:36 UTC

Tirgus saruna

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025. g. 8. sept. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. sept. 16:16 UTC

Peļņas

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025. g. 8. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 8. sept. 16:04 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

TG Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

1.43% augšup

Prognoze 12 mēnešiem

Vidējais 32.67 USD  1.43%

Augstākais 50 USD

Zemākais 11 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi TG Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

3 ratings

1

Pirkt

1

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 34.86Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

97 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat